Seneca Biopharma, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Rockville MD United States (1996)
Status: Acquired by Leading BioSciences, Inc (2021)

Organization Overview

First Clinical Trial
2011
NCT01310881
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Suzhou Neuralstem Biopharmaceuticals

Active Ingredients

Drugs in Phase 2 Trials (2)

Key: Seneca Biopharma, Inc. (0) Acquired (2)

nsi-189 (3 trials)

tranexamic acid (cyklokapron) (4 trials)

Drugs in Phase 1 Trials (4)

Key: Seneca Biopharma, Inc. (0) Acquired (4)

cellulose (1 trial)

human spinal cord stem cells (1 trial)

nsi-566 (1 trial)

zd03 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Ischemia (Phase 1)

Spinal Cord Injuries (Phase 1)

Stroke (Phase 1)

Overview

  • Highest Phase: None
  • # of Trials: 10
  • # of Trial APIs: 6